Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Replimune Group (REPL) has drawn attention after presenting updated clinical data from its IGNYTE phase 2 trial at the ESMO Congress 2025. The study combined RP1 with nivolumab in patients with acral ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

I am selling my remaining shares in TARS for 90% gain. I am adding to my position in DERM on the dip back to $7. I am initiating a new position in REPL with 5% portfolio weighting. REPL- FDA's ...

While we would’ve recommended using Nova Launcher in the past, the app’s development has practically ground to a halt. After the company behind the launcher was purchased, its development team was ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...

Voted a Top Place to Work for four straight years, IT Services at Miami University in Oxford, Ohio is dedicated to providing comprehensive support to students, faculty, and staff.

Getting ready for a Java interview in 2025? It can feel like a lot, especially with so many different things to know. Whether you’re just starting out or you’ve been coding for a while, this guide is ...

Try it now — load your own PDF or use the sample: ...